Cyrus Arman, Ph.D., the new President of CytoDyn, discusses the potential of the company’s lead candidate leronlimab for the treatment of HIV, solid tumors, and nonalcoholic fatty liver disease / nonalcoholic steatohepatitis, as well as his plans for putting the company on a new path toward success.
.svg)
